))
Let's Talk MND - Michael Thurn CEO PharmAust
Manage episode 430684528 series 3562494
Jane Simpson에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Jane Simpson 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Our guest this week is Michael Thurn the CEO and Managing Director of PharmAust, a clinical-stage biotechnology company.
He tells us about Monepantel which is a well-known veterinary drug. It has been shown to have an effect on the abnormal accumulation of protein in cells. This accumulation is associated with motor neurone disease. Monepantel works by increasing the recycling and removal of excessive or abnormal proteins.
Results from phase 1 of this trial suggest that monepantel was well tolerated. In fact it showed a slowing in progression of MND.
In July of 2024 Monepantel has been included in the Healy ALS trials, in Boston, USA, which means the study will be fast tracked.
To learn more about the studies please go to
34 에피소드
공유
